The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Therapeutics of Neurotransmitters in Alzheimer’s Disease
Open accessAbstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease, characterized by the loss of memory, multiple cognitive impairments and changes in the personality and behavior. Several decades of intense research have revealed that multiple cellular changes are involved in disease process, including synaptic damage, mitochondrial abnormalities and inflammatory responses, in addition to formation and accumulation of amyloid-β (Aβ) and phosphorylated tau. Although tremendous progress has been made in understanding the impact of neurotransmitters in the progression and pathogenesis of AD, we still do not have a drug molecule associated with neurotransmitter(s) that can delay disease process in elderly individuals and/or restore cognitive functions in AD patients. The purpose of our article is to assess the latest developments in neurotransmitters research using cell and mouse models of AD. We also updated the current status of clinical trials using neurotransmitters’ agonists/antagonists in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Tsamis, K. I., Mytilinaios, D. G., Njau, S. N., & Balogiannis, S. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310050002 · Cited by 21
Hautzel, H., Müller, H. W., & Nikolaus, S. (2014) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0647-14-03 · Cited by 18
Zlomuzica, A., Dere, D., & Dere, E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.08.008 · Cited by 18
Jing-ying, Jia, J., Qian‐Hua, Zhao, Yun, Y., Liu, YuZHOU, Gang-yi, Dayuan, Zhu, et al. (2013) · 中国药理学报:英文版 · Cited by 17
Losi, G., Lanza, M., Makovec, F., Artusi, R., Caselli, G., & Puia, G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.09.002 · Cited by 16
Tsentsevitsky, A. N., Faritovich, N. L., Nikolsky, E. E., & Malomouzh, A. I. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23977 · Cited by 13
Le système histaminergique : une cible pour de nouveaux traitements des deficits cognitifs
Motawaj, M., Burban, A., Davenas, E., Gbahou, F., Faucard, R., Morisset‐Lopez, S., & Arrang, J. (2010) · Therapies · doi:10.2515/therapie/2010058 · Cited by 9
Sheng, N., Yang, J. Y., Silm, K., Edwards, R. H., & Nicoll, R. A. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.028 · Cited by 9
GABAA-Rezeptorfunktion im Fokus
Nikolaus, S., Hautzel, H., & Müller, H. W. (2014) · Nuklearmedizin - NuclearMedicine · Cited by 8
(2000) · doi:10.1002/1531-8249(200012)48:6
Cited by
Gut microbiota and dysbiosis in Alzheimer's disease: Implications for pathogenesis and treatment
Liu, S., Gao, J., Zhu, M., Liu, K., & Zhang, H.-L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02073-3 · Cited by 516
The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease
the Synaptic Health Endpoints Working Group, Colom-Cadena, M., Spires-Jones, T., Zetterberg, H., Blennow, K., Caggiano, A., DeKosky, S. T., Fillit, H., Harrison, J. E., Schneider, L. S., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00588-4 · Cited by 328
Revisiting the role of neurotransmitters in epilepsy: An updated review
Akyuz, E., Polat, A. K., Eroglu, E., Kullu, I., Angelopoulou, E., & Paudel, Y. N. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118826 · Cited by 303
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Jeon, M.-T., Kim, K.-S., Kim, E. S., Lee, S., Kim, J., Hoe, H.-S., & Kim, D.-G. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101333 · Cited by 76
Metadata
- Authors
- Kandimalla, R., & Reddy, P. H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-02-15
- Volume
- 57
- Issue
- 4
- Pages
- 1049-1069
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2588517921
- Cited by
- 268
- References
- 210
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.